There’s no routine screening for pancreatic cancer, most cases aren’t operable, and the five year survival rate after diagnosis is around 13%. It’s a traumatic news.
But new personalized mRNA immunotherapy is showing encouraging results in Phase 1 clinical trials.
Keep funding science!
Scientists caution that more research is needed, but nearly all of the patients who responded to the personalized vaccine are still alive six years later.
